BioNotebook: Aerie, Dynavax, Tetraphase, MEI Pharma, Sorrento, Can-Fite
This article was originally published in Scrip
Aerie prices $67.2m IPO; Dynavax sells $132.2m in stock, debt; Tetraphase plans $40m offering; MEI prices $35m offering; Sorrento joins Nasdaq, raises $30m; and Can-Fite garners $6m in Tel Aviv.
You may also be interested in...
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.